Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 12, 2001, to announce the issuance of a press release dated the same day. The specific content of this press release, which constitutes the material event being reported, is not detailed within the 8-K itself but is included as an exhibit. Investors should refer to the accompanying press release for the substantive details of the announcement made by Regeneron on October 11-12, 2001. This filing serves primarily as a notification of the release of new information to the public.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report (8-K) on October 12, 2001.
- 2The primary purpose of the filing is to report an event that occurred on October 11, 2001.
- 3This event was the issuance of a press release by the Company.
- 4The press release dated October 12, 2001, is included as an exhibit to this 8-K filing.
- 5The filing does not disclose the specific content of the press release, directing investors to the exhibit for details.
- 6Stuart Kolinski, Vice President & General Counsel, signed the report.